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Abstract
Background: Detection of Loss of Heterozygosity (LOH) is one of the most common molecular
applications in the study of human diseases, in particular cancer. The technique is commonly used to
examine whether a known tumour suppressor gene is inactivated or to map unknown tumour suppressor
gene(s). However, with the increasing number of samples analysed using different software, no tool is
currently available to integrate and facilitate the extensive and efficient data retrieval and analyses, such as
correlation of LOH data with various clinical data sets.
Results: An algorithm to identify prognostic disease markers is devised and implemented as novel
software called LDMAS. LDMAS is a software suite designed for data retrieval, management and integrated
analysis of the clinico-pathological data and molecular results from independent databases. LDMAS is used
in stratification of disease stages according to clinical stage or histological features and correlation of
various clinico-pathological features with molecular findings to obtain relevant prognostic markers such as
those used in predicting the outcome of cervical intraepithelial neoplasia (CIN). This approach lead to the
identification of novel prognostic cervical cancer markers and extraction of useful clinical information such
as correlation of Human Papilloma Virus (HPV) status with CIN lesions.
Conclusions: A novel software called LDMAS is implemented and used to extract and identify prognostic
disease markers. The software is used to successfully identify 4 novel prognostic markers that can be used
to predict the outcome of CIN. LDMAS provides an essential platform for the extraction of useful
information from large amount of data generated by LOH studies. LDMAS provides three unique and
novel features for LOH analysis : (1) automatic extraction of relevant data from patient records and
reports (2) correlation of LOH data with clinico-pathological data and (3) storage of complex data in
flexible format. The first feature automates the creation of database of clinically relevant information from
huge amount of data, the second feature extracts useful biomedical information such as prognostic
markers in CIN and the third feature simplifies the statistical analyses of the data and allows non-
statisticians to carry out the analysis. Additionally, LDMAS can be used to extract clinically useful markers
from other diseases and interface to high throughput genotyping analysis software such as GDAS used to
generate LOH data from Affymetrix® GeneChip Mapping arrays.
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Detection of LOH is one of the most common molecular
applications in the study of human diseases, in particular
cancer. It is commonly used to examine whether a known
tumour suppressor gene is inactivated or to map
unknown tumour suppressor gene(s). Detection of LOH
not only helps in understanding the molecular mecha-
nisms underlying the development of cancer, but also
provides important information useful for disease diag-
nosis and prognosis. LOH detection is commonly carried
out by the analysis of microsatellite markers using an
automated DNA sequencer. With the raw data from the
sequencer being stored in one file per lane together with
corresponding clinical information and patient follow up
data, each LOH study [1,2] generates hundred of files that
need to be organised and related in a structured format.
However, with the increasing number of samples analysed
using different software, no tool is currently available to
facilitate the extensive and efficient data retrieval and
analyses, such as correlation of LOH data with various
clinical data sets. We have developed a novel software
package: LOH Data Management and Analysis Software
(LDMAS) in order to satisfy these needs. LDMAS can
retrieve LOH data from automated DNA sequencer plat-
form and clinical data from any patient record system and
correlate different data sets according to the user's choice.
Here we present how LDMAS interfaces to Genotyper soft-
ware (ABI, Foster City, CA) which is used to determine the
presence of LOH, and the patient record system SunQuest
(San Francisco, CA), facilitating the identification of LOH
markers associated with the development of CIN [3]. CIN
show variable clinical behaviour despite morphological
homogeneity within each subgroup. Clinically, it is vital
to distinguish CIN lesions with different behaviour and
identify those likely to persist and progress despite
treatment.
Implementation
System architecture
LDMAS package is composed of three modules:
(1) MRES (Medical Report Extractor Software) which
parses patient report files, extracts the information of
interest and organises it into a structured format, applica-
ble to LDAS
(2) LDAS (LOH Data Analysis Software) which obtains
LOH data from Genotyper (Applied Biosystems, Califor-
nia) or GDAS (Affymetrix, California) software and corre-
lates it to clinical data obtained from MRES
(3) LDMS (LOH Data Management Software) which is
used to gather patients' clinico-pathological data and
extract significant relationship between the various data
sets
LDAS and LDMS work synergistically to manage and ana-
lyse LOH data. The MRES source code for automatic pars-
ing of patient reports is written in C++ using C++ Builder
5.0 (Borland Software Corporation, Scotts Valley, CA),
LDAS is written in Visual Basic for Application as an Excel
2000 add-in and LDMS is written as Visual Basic for Appli-
cation modules embedded within Access 2000 as fully
functional software. These modules can be run independ-
ently and used for applications other than LOH. LDMAS
runs on Microsoft® Windows 2000 or Windows XP operat-
ing system. Figure 1 shows LDMAS architecture.
Type of input data for LDMAS modules
The MRES module takes its input from any patient report
file containing clinical details such as diagnosis, stage of
the disease, treatment and follow up results, parses and
formats patient's data into a structured format that can be
saved as Excel spreadsheet. In this case, data were taken
from SunQuest patient record system and MRES con-
verted and produced the data as:
(1) Hospital Number
(2) Hospital ID
(3) Patient Name
(4) Date of Birth
(5) Pathological specimen Number
(6) Date of Diagnosis
(7) Histological diagnosis.
The user can manually check the data and use it as tem-
plate for analysis. Data analysis is carried out using LDAS
which obtains LOH data from Genotyper and correlates it
to the clinical data obtained from MRES. LDAS obtains
data in plain text format and can thus be easily interfaced
to any LOH platform generating software such as Genoty-
per and GDAS. Finally all data are entered into LDMS for
storage and intelligent mining of data. Database query
results can be exported back to LDAS allowing correlation
between LOH and various clinico-pathological parame-
ters such as age, histological grade, treatment modality
and their responses, and HPV status as well as carry out
multivariate analysis to determine the sensitivity and spe-
cificity of the markers involved in the LOH study. A more
detailed description of all the modules is provided in
LDMAS user's guide [Additional file 1] and the example
below.Page 2 of 6
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LDMAS offers several advantages to users. It is user
friendly and its architecture is modular allowing versatil-
ity of use. It enforces the standardisation of procedures for
studies involving large cohorts of individuals. The data is
well organized since LDMAS systematically assigns LOH
results of each case to its corresponding clinical informa-
tion. Additionally, LDAS standardizes LOH data analysis
implicitly and allows the user to edit the data manually if
needed. Microsoft Excel has been chosen to implement
LDAS because of its wide use, versatility and convenient
statistical analysis features facilitating the implementation
of multivariate analysis and correlation testing between
LOH and clinico-pathological parameters.
Results and discussion
LDMAS application in identification of LOH markers 
associated with persistence / progression of cervical 
intraepithelial neoplasia
We divided the CIN groups into disease free indicating
cases that become CIN free after treatment, and disease
persistence/progression indicating cases that develop
show progression or persistence of CIN despite treatment.
We used LDMAS to retrospectively examine the prognos-
tic value of LOH at 12 microsatellite markers including 10
from 3p14, 3p22-21, 6p21 and 11q23 which are fre-
quently deleted in cervical cancer [3,4], in 164 cases of
CIN lesions using archival cytological/histological speci-
mens. LOH was further correlated with high risk HPV
infection.
Initially MRES was used to automatically parse 4300
patient records and extract clinico-pathological data
including age, diagnosis, method of treatment and treat-
ment response during follow up. Out of those, 164 cases
with follow up of 3 or more years were chosen for the
study and their clinico-pathological information was
imported into LDAS. Initially, 71 out of the 164 selected
cases were examined for LOH using 12 fluorescent micro-
satellite markers ran on ABI377 DNA Sequencer. LDAS
was then used to identify the microsatellite markers for
which LOH was significantly associated with disease per-
sistence/progression of CIN using two tailed student t-
test. Figure 2 generated using LDAS shows that microsat-
ellite markers D3S1300 (3p14.2), D3S1260 (3p22.2),
D11S35 (11q22.1) and D11S528 (11q23.3) have the
highest LOH in CIN lesions displaying persistence/pro-
gression than those who were disease free during follow
up [5].
Example of output from LDMASFigure 2
Example of output from LDMAS. LDMAS generated histogram showing the best set of LOH markers in cervical cancer high-
lighted by *. DF indicates Disease Free and DP indicates Disease Persistence/Progression CIN cases.Page 4 of 6
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To validate this finding, LOH at these four markers was
investigated in a further series of 93 cases. Compatible
results were obtained from these additional cases.
The two sets of data were combined and further compared
using LDMS. Methodologies included :
1) comparison using χ2 (chi-squared) test of LOH at each
of the four microsatellite markers with age, various meth-
ods of treatment, different subtypes of HPV infection and
between CINs showing disease free or disease persistence/
progression.
2) correlation of LOH data with histological grade of CIN,
treatment response and various HPV subtypes.
Through such complex analysis, we showed that concur-
rent LOH at two of the four microsatellite markers could
identify 47% of CINs that showed disease persistence/
progression with 100% specificity [5]. Furthermore, LOH
at D3S1300 was found to be significantly associated with
HPV16 infection. Part of this data analysis is supplied in
the LDMAS guide [see Additional file 1]. More detailed
analysis of this study is described in [5].
Algorithm for identifying prognostic disease markers
Based on the above example, an algorithm can be devel-
oped to extract prognostic markers for other diseases. The
algorithm can be summarised in the following pseudoc-
ode :
(1) Divide the disease in groups according to the pathol-
ogy staging
(2) Parse patient data from clinical records and use the
groups defined in part (1)
(3) FOR each microsatellite marker
carry out a two tailed student t-test between the disease
groups using LOH data
IF t-test p ≤ 0.05
Marker is significant in prognosis of the disease
ELSE
Marker is not significant in prognosis of the disease
(4) Validate the prognostic markers using χ2 (chi-squared)
test of LOH with clinico-pathological data and correlation
of LOH data with histological grade of CIN, treatment
response and various HPV subtypes.
LDMAS has been implemented using the above
pseudocode.
Conclusions
We have devised an effective algorithm to identify and
extract useful markers that can be used to predict the out-
come of disease and used the algorithm to successfully
identify 4 novel prognostic markers that can be used to
predict the outcome of CIN. The algorithm was imple-
mented in a novel software called LDMAS which provides
an essential platform for the extraction of useful informa-
tion from large amount of data generated by LOH studies.
Furthermore, LDMAS is used to efficiently store, manage
and track the data. Its flexible nature allows the easy
manipulation of data facilitating complex analysis as
demonstrated in the current study. The various modules
of LDMAS can be easily adapted and used with other
applications such as high throughput LOH and genotyp-
ing using SNPs on Affymetrix® GeneChip Mapping arrays
and fingerprinting studies. Modules such as MRES can be
used independently to parse medical records facilitating
extraction of specific clinical information of interest.
Additionally, LDMAS can be used to extract clinically use-
ful markers for other diseases.
Availability and requirements
The source code and executable files for LDMAS modules
as well as user manual including examples from real study
data are freely available and can downloaded from our
website at : http://molpath.his.path.cam.ac.uk/bioinfor
matics/LDMAS.shtml
Additionally examples of input files are provided from
our website for users to test the software and assess its
functionality.
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